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Abstract: N-Palmitoyl-ethanolamine (PEA) is an anti-inflammatory component of egg yolk that is
usually employed for the prevention of respiratory apparatus virus infection and then frequently
used for its efficient anti-inflammatory and analgesic effects in experimental models of visceral,
neuropathic, and inflammatory diseases. Nevertheless, data of its use in animal or human therapy
are still scarce and further studies are needed. Herein, we report the biological evaluation of a small
library of N-palmitoyl-ethanolamine analogues or derivatives, characterized by a protected acid
function (either as palmitoyl amides or hexadecyl esters), useful to decrease their hydrolysis rate
in vitro and prolong their biological activity. Two of these compounds—namely phenyl-carbamic acid
hexadecyl ester (4) and 2-methyl-pentadecanoic acid (4-nitro-phenyl)-amide (5)—have shown good
anti-inflammatory and antioxidant properties, without affecting the viability of J774A.1 macrophages.
Finally, crystals suitable for X-ray analysis of compound 4 have been obtained, and its solved crystal
structure is here reported. Our outcomes may be helpful for a rational drug design based on new
PEA analogues/derivatives with improved biological properties.
Keywords: N-acyl-ethanolamines; N-palmitoyl-ethanolamine derivatives; biological evaluation of
PEA derivatives; anti-inflammatory activity; antioxidant properties; crystallographic studies
1. Introduction
N-acyl-ethanolamines (NAEs) are well known to be endogenous bioactive amides showing
biosynthetic and metabolic pathways [1]. Among this class of compounds, we must mention:
(i) N-arachidonoyl-ethanolamine (anandamide, AEA, Figure 1), the first endocannabinoid that was
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discovered; (ii) the anorectic mediator N-oleoyl-ethanolamine (OEA); (iii) N-palmitoyl-ethanolamine
(PEA), known since the late 1950s as an anti-inflammatory component of egg yolk and employed with
the brand name of impulsin in the prevention of viral infection of the respiratory apparatus [2,3].
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Figure 1. Chemical structures of some of the most studied bioactive N-acyl-ethanolamines (NAEs). 
Within the fatty acid ethanolamides, palmitoyl ethanolamide (PEA) has attracted great attention, 
since it has been found abundantly in the central nervous system (CNS). Its physiological and 
pharmacological properties have been analyzed, and its therapeutic efficacy in several central 
nervous system disorders related to pain and inflammation have been thoroughly examined [4]. 
Nowadays, N-palmitoyl-ethanolamine is recognized worldwide for its efficient anti-inflammatory 
and analgesic effects in experimental models of visceral, neuropathic, and inflammatory diseases, 
acting through several possible mechanisms. However, so far scarce experimental data have been 
reported about PEA’s use in animals, or particularly, humans [5]. 
Under inflammatory and neurodegenerative conditions, the fatty acid amide PEA acts as a  
“on-demand” protective endogenous mediator to counteract inflammation, neuronal damage, and 
pain itself. 
Some works have demonstrated that, as for the analogous endocannabinoids AEA and  
2-arachidonoylglycerol, PEA tissue concentrations are modified during pathological conditions [6]. 
PEA also appears to be involved in several endogenous mechanisms of protection or in-body 
response to different types of damage, where a decrease in PEA levels produces an inflammatory reaction. 
Furthermore, a decrease in endogenous levels of PEA has been found in the spinal cord in an 
animal model of neuropathic pain, suggesting that this reduction in response to a damage may affect 
the inflammatory response [7,8]. 
Some studies have demonstrated that neuroprotective or anti-inflammatory PEA effects may be 
due to new G-protein coupled receptors in microglial cells [9] or to PPAR-a [10], respectively, whereas 
they remain unaffected by cannabinoid receptor antagonists. PPAR-a is a nuclear receptor that plays 
a key role in lipid nutrient employment and inflammation [10,11]. After an initial activation through 
ligand binding (which produces conformational changes in receptor conformation), PPAR-a forms a 
heterodimer formation with the 9-cis-retinoic acid receptor, enrolls coactivators and the resulting 
multiprotein complex, and regulates the transcription of responsive genes. PEA anti-inflammatory 
effects result from its ability to activate PPAR-a-dependent gene transcription with a time delay of 
several hours [11–13]. 
Other mechanisms have been proposed to explain PEA’s anti-inflammatory and analgesic effects, 
such as: (i) Mast-cell degranulation down-regulation via an “autacoid local inflammation antagonism” 
(ALIA) effect [14]; (ii) the so-called “entourage effect”, which postulates [15,16] that PEA acts by enhancing 
the anti-inflammatory and anti-nociceptive effects exerted by AEA, often produced together with 
PEA, and activates cannabinoid (CB) 1 and 2 receptors or the transient receptor potential vanilloid 
receptor type 1, TRPV1 channels [17,18]. CB1 and CB2 [19,20] are two G-protein coupled receptors sharing 
50% sequence identity, and are strongly expressed in the nervous and immune system, respectively 
[21,22]. The search for CB receptors’ endogenous ligands—so-called “endocannabinoids”—has given 
rise to the identification of two major classes of lipids capable of activating these receptors; namely, 
the N-acyl ethanolamines (NAEs) and the monoacylglycerols (MAGs) [23,24]. 
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Within the fatty acid ethanolamides, palmitoyl ethanolamide (PEA) has attracted great attention,
since it has been found abundantly in the central nervous system (CNS). Its physiological and
pharmacological properties have been analyzed, and its therapeutic efficacy in several central nervous
system disorders related to pain and inflammation have been thoroughly examined [4].
Nowadays, N-palmitoyl-ethanolamine is recognized worldwide for its efficient anti-inflammatory
and analgesic effects in experimental models of visceral, neuropathic, and inflammatory diseases,
acting through several possible mechanisms. However, so far scarce experimental data have been
reported about PEA’s use in animals, or particularly, humans [5].
Under inflammatory and neurodegenerative conditions, the fatty acid amide PEA acts as
a “on-demand” protective endogenous mediator to counteract inflammation, neuronal damage,
and pain itself.
Some works have demonstrated that, as for the analogous endocannabinoids AEA and
2-arachidonoylglycerol, PEA tissue concentrations are modified during pathological conditions [6].
PEA also appears to be involved in several endogenous mechanisms of protection or in-body response
to different types of damage, where a decrease in PEA levels produces an inflammatory reaction.
Furthermore, a decrease in endogenous levels of PEA has been found in the spinal cord in an
animal model of neuropathic pain, suggesting that this reduction in response to a damage may affect
the inflammatory response [7,8].
Some studies have demonstrated that neuroprotective or anti-inflammatory PEA effects may be
due to new G-protein coupled receptors in microglial cells [9] or to PPAR-a [10], respectively, whereas
they remain unaffected by cannabinoid receptor antagonists. PPAR-a is a nuclear receptor that plays a
key role in lipid nutrient employment and inflammation [10,11]. After an initial activation through
ligand binding (which produces conformational changes in receptor conformation), PPAR-a forms
a heterodimer formation with the 9-cis-retinoic acid receptor, enrolls coactivators and the resulting
multiprotein complex, and regulates the transcription of responsive genes. PEA anti-inflammatory
effects result from its ability to activate PPAR-a-dependent gene transcription with a time delay of
several hours [11–13].
Other mechanisms have been proposed to explain PEA’s anti-inflammatory and analgesic
effects, such as: (i) Mast-cell degranulation down-regulation via an “autacoid local inflammation
antagonism” (ALIA) effect [14]; (ii) the so-called “entourage effect”, which postulates [15,16] that
PEA acts by enhancing the anti-inflammatory and anti-nociceptive effects exerted by AEA, often
produced together with PEA, and activates cannabinoid (CB) 1 and 2 receptors or the transient receptor
potential vanilloid receptor type 1, TRPV1 channels [17,18]. CB1 and CB2 [19,20] are two G-protein
coupled receptors sharing 50% sequence identity, and are strongly expressed in the nervous and
immune system, respectively [21,22]. The search for CB receptors’ endogenous ligands—so-called
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“endocannabinoids”—has given rise to the identification of two major classes of lipids capable of
activating these receptors; namely, the N-acyl ethanolamines (NAEs) and the monoacylglycerols
(MAGs) [23,24].
In the search for novel anti-inflammatory drugs related to natural sources (e.g., a series of
flavanones isolated from the Amygdalus lycioides Spach [25,26]), we thought it worthwhile to prepare
promising PEA derivatives/analogues with potential anti-inflammatory and antioxidant activity.
The aim of this work is the biological evaluation of a small library of PEA analogues or
derivatives, 1–6, characterized by a protected acid function, prepared by some of us [27,28], which
could bring a decreased hydrolysis rate in a living system (Figure 2). Compound 4, together with
2-methyl-pentadecanoic acid (4-nitro-phenyl)-amide (5), has demonstrated an interesting antioxidant
and anti-inflammatory activity. Finally, crystals of phenyl-carbamic acid hexadecyl ester (4)—suitable
for X-ray analysis—have been obtained, and the solved crystal structure is reported.
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2. Results and Discussion
2.1. Crystal Structure Determination of 4
Good crystals of 4, suitable for X-ray diffractometry analysis, have been obtained. An ORTEP
view of 4 is given in Figure 3. The PEA deriv tive 4 crystallizes in the centrosymmetric orthorhombic
space group Pbca, with one molecule in the asymmetric unit (Z = 8).
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The carbon atoms of the alkyl chain are arranged in a classical zig-zag fashion, with all C–C
units staggered and in anti-conformation. The mean plan fitted through the atoms chain have an rms
deviation of 0.0419 Å and form an angle of 14.5◦ with the plane fitted through the amide group, which
is in turn tilted 21.8◦ from the phenyl ring.
There is only one strong intermolecular interaction in the crystal structure, which is a hydrogen
bond between the amide hydrogen atom of one molecule and the carboxyl oxygen of an adjacent
molecule (N-HO 2.849(3) Å) that generates infinite supramolecular chains running along the b axis.
The molecules are arranged in parallel, but in two alternating distinct orientations (Figure 3) forming
an angle of about 50◦ degrees.
Very weak van der Waals interactions are also present in the packing, involving the hydrogen
atoms of the phenyl groups, while no pi–pi stacking is observed.
2.2. Compounds 4 and 5 Exert Macrophage Viability
Our data indicated that macrophages viability was not affected by 4 and 5 treatment (data not
shown).
2.3. Compounds 4 and 5 Exert Anti-Inflammatory and Antioxidant Activity
To assess the effect of 4 and 5 in influencing NO production, we measured nitrite release—a stable
end-product of NO—in cellular medium of lipopolysaccharide (LPS)-stimulated murine macrophage
cell line J774A.1 in the presence of 4 and 5 (200–25 µM).
When 4 and 5 (200–25 µM) were added to J774A.1 macrophages 1 h before and simultaneously to
LPS (1 µg/mL) stimulation, a significant reduction in NO release in J774A.1 was observed (p < 0.001
vs. LPS; Figure 4A).
In particular, 4 significantly inhibited NO in a concentration range of 200–50 µM, while 5
significantly inhibited NO release only at 200 µM (p < 0.001 vs. LPS; Figure 4A). Between the two
different extracts, 4 exerted the highest inhibitory effect on NO release (p < 0.001 vs. 5; Figure 4A).
To further confirm the observed effect of 4 compared to 5 during LPS-induced inflammation,
we evaluate iNOS and COX-2 expression in LPS-treated macrophages. In J774A.1 macrophages,
4 significantly inhibited iNOS at all the tested concentrations (p < 0.05 vs. LPS; Figure 4B) and
COX-2 expression in a range concentration of 200–50 µM (p < 0.05 vs. LPS; Figure 4C). In addition,
5 significantly inhibited iNOS in a µM concentration range (p < 0.001 vs. LPS; Figure 4B) and COX-2
expression in a µM concentration range (p < 0.001 vs. LPS; Figure 4C).
When 4 and 5 (200–25 µM) were added to J774A.1 macrophages 1 h before and simultaneously to
LPS stimulation, they significantly inhibited ROS production in cell medium (p < 0.01 vs. LPS; Figure 5A).
In particular, 4 significantly inhibited ROS release at all the tested concentrations (p < 0.001 vs. LPS;
Figure 5A), while 5 significantly inhibited ROS release in a concentration range 200–50 µM (p < 0.01
vs. LPS; Figure 5A). Between the two different extracts, 4 exerted the highest inhibitory effect on ROS
production (p < 0.01 vs. 5; Figure 5A).
In J774A.1 macrophages, both 4 and 5 (200–25 µM) increased HO-1 and SOD-1 expression
(Figures 3C and 5B).
In particular, 4 significantly increased HO-1 expression at the concentrations of 100 and 200 µM
(p < 0.05 and p < 0.001 vs. LPS; Figure 5B), while 5 increased HO-1 expression only at the highest
concentration (p < 0.05 vs. LPS; Figure 5B). Moreover, 4 also increased SOD expression at the highest
tested concentration (p < 0.05 vs. LPS; Figure 5C).
Compounds 4 and 5 showed an interesting anti-inflammatory potential. Our results indicate that
they were able to inhibit NO release by LPS-treated J774A.1 macrophages. NO is a pro-inflammatory
mediator released by LPS-treated macrophages, and iNOS is the main isoform involved in NO release
during inflammation [30,31]. Interestingly, compounds 4 and 5 also significantly inhibited iNOS
expression in macrophages, indicating their inhibitory effect on both the iNOS activity and expression.
Moreover, their anti-inflammatory activity was also tested on another important pro-inflammatory
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enzyme, COX-2. The obtained results indicated that compounds 4 and 5 also significantly inhibit
COX-2 expression. Finally, it is noteworthy that ROS are essential mediators both in inflammatory
response and in oxidative stress conditions, so we evaluated the effect of the studied compounds on
ROS production. Compounds 4 and 5 significantly inhibited ROS production and up-regulated HO-1
expression. HO-1 is the rate-limiting enzyme in heme degradation, and catalyzes the oxidation of
heme to generate several biologically-active molecules, such as carbon monoxide (CO), biliverdin, and
ferrous ion [32]. HO-1 can increase cellular antioxidant status by generating [33] antioxidants such
as bilirubin, which can contribute to an inhibition of iNOS protein expression and a suppression of
NO production. HO-1 is normally expressed at low levels in most tissues/organs, except for spleen;
however, it is highly inducible in response to a variety of stimuli (e.g., LPS), to protect cells against
oxidative and inflammatory injury [34,35].
Taken together, our results indicate that the examined compounds 4 and 5 possess good
anti-inflammatory and antioxidant properties, without exerting cytotoxic effects on macrophages.
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iNOS and (C) COX-2 expression in macrophages J774A.1. Values, mean ± S.E.M., are expressed as
% of inhibition vs. J774A.1 treated with LPS alone in at least three independent experiments with
three replicates each. Comparisons were performed using one-way analysis of variance, and multiple
comparisons were made by Bonferroni’s test. ***, **, and * denote p < 0.001, p < 0.01, and p < 0.05 vs.
LPS, respectively. ### denotes p < 0.001 vs. 5.
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3.1. Chemistry 
All chemical reagents were of analytical grade, purchased from commercial suppliers and used 
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were prepared by following already-published synthetic procedures [27]. 
3.2. Cell Culture 
J774A.1 murine monocyte/macrophage cell line (American Type Culture Collection, Rockville, 
MD, USA) was grown in adhesion on Petri dishes and maintained with Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal calf serum (FCS), 25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 2 mM glutamine, 100 U/mL penicillin and 100 mg/mL 
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Figure 5. (A) Effect of 4 and 5 (200–25 µM) on LPS-induced reactive oxygen species (ROS) in
LPS-stimulated J774A.1 macrophages. Effect of 4 and 5 (200–25 µM) on (B) LPS-induced HO-1
and on (C) LPS-induced Superoxide dismutase SOD expression in macrophages J774A.1. Values,
mean ± S.E.M. are expressed as % of inhibition vs. J774A.1 treated with LPS alone and as mean
fluorescence intensity of at least three independent experiments ith three replicates each. Comparisons
were performed using one-way analysis of variance, and multiple comparisons were made by
Bonferroni’s test. ***, **, and * denote p < 0.001, p < 0.01, and p < 0.05 vs. LPS, respectively. ### denotes
p < 0.001 vs. 5.
3. Materials and Methods
3.1. Chemistry
All chemical reagents were of analytical grade, purchased from commercial suppliers and used as
received without further purification, unless otherwise noted. The PEA analogues/derivatives 1–6
were prepared by following already-published synthetic procedures [27].
3.2. Cell Culture
J774A.1 murine monocyte/macrophage cell line (American Type Culture Collection,
Rockville, MD, USA) was grown in adhesion on Petri dishes and maintained with Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS), 25 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 2 mM glutamine, 100 U/mL penicillin
and 100 mg/mL streptomycin at 37 ◦C in a 5% CO2 atmosphere.
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3.3. Viability Assay
Cells (5.0 × 104/well) were plated on 96-well plates and allowed to adhere for 4 h.
Thereafter, the medium was replaced with fresh medium, serial dilutions of our compounds
(200–25 µM) were added, and cells were incubated for 24, 48, and 72 h [36–38]. Mitochondrial
respiration—an indicator of cell viability—was assessed by the mitochondrial-dependent reduction
of (3-(4,5-dimethylthiazol-2-yl)-2,5-phenyl-2H-tetrazolium bromide) (MTT) to formazan, and cells’
viability was assessed according to the method of Mosmann, as previously reported [39,40]. Briefly,
5 µL of MTT (5 mg/mL) was added and the cells were incubated for 3 h. Thereafter, the cells
were lysed and the dark blue crystals solubilized with 100 µL of a solution containing 50% (v:v)
N,N-dimethylformamide, 20% (w:v) SDS with an adjusted pH of 4.5. The optical density (OD) of
each well was measured with a microplate spectrophotometer (Titertek Multiskan MCC/340, Titertek
Instruments Inc., Huntsville, AL, USA) equipped with a 620-nm filter. The viability of the cell line
in response to treatment with tested compounds was calculated as: Percent dead cells = 100 − (OD
treated/OD control) × 100.
3.4. Nitrite Determination
J774A.1 macrophages were seeded into 24-well plates (3.0× 105 cells/well) and allowed to adhere
for 4 h. Thereafter, the medium was replaced with fresh medium and cells were pretreated with 4 and
5 (200–25 µM) for 1 h and then co-exposed to LPS (1 µg/mL) for 24 h. NO generation was measured as
nitrite (NO2, µM), indicating NO release by cells in the culture medium, as previously reported [41,42].
NO2 amounts were measured by Griess reaction. Briefly, 100 µL of cell culture medium were mixed
with 100 µL of Griess reagent-equal volumes of 1% (w:v) sulphanilamide in 5% (v:v) phosphoric
acid and 0.1% (w:v) naphtylethylenediamine–HCl and incubated at room temperature for 10 min,
then the absorbance was measured at 550 nm in a Titertek microplate reader (Dasit, Cornaredo,
Milan, Italy). The amount of NO2, as µM concentration, in the samples was calculated by a sodium
nitrite standard curve.
3.5. Measurement of Intracellular ROS
ROS formation was evaluated through the probe 2′,7′-dichlorofluorescein-diacetate (H2DCF-DA)
as previously reported [43]. H2DCF-DA is a non-fluorescent permeant molecule that passively diffuses
into cells, where the acetates are cleaved by intracellular esterases to form H2DCF, thereby trapping it
within the cell. In the presence of intracellular ROS, H2DCF is rapidly oxidized to the highly fluorescent
2′,7′-dichlorofluorescein (DCF). Briefly, J774A.1 cells were plated at a density of 3.0 × 105 cells/well
into 24-well plates. Cells were allowed to grow for 4 h; thereafter, the medium was replaced with
fresh medium, and cells were incubated with 4 and 5 (200–25 µM) for 1 h and then co-exposed to
LPS (1 µg/mL) for 24 h. Cells were then collected, washed twice with phosphate buffered saline
(PBS), and incubated in PBS containing H2DCF-DA (10 µM) at 37 ◦C. After 45 min, cells’ fluorescence
was evaluated using fluorescence-activated cell sorting (FAC Sscan; Becton Dickinson, #342975 BD
Biosciences; San Josè, CA, USA) and elaborated with Cell Quest software (BD Biosciences). Data are
expressed as mean fluorescence intensity.
3.6. Measurement of iNOS, COX-2, HO-1, and SOD Expression by Cytofluorimetry
J774A.1 cells were plated into 96-well plates (5 × 104 cells/well) and treated with 4 and 5
(200–25 µM) for 1 h and then co-exposed to LPS (1 µg/mL) for 24 h. Cells were then collected,
washed twice with PBS, and then incubated in fixing solution for 20 min at 4 ◦C and then incubated
in Fix PermSolution for 30 min at 4 ◦C. Anti-iNOS (e-Bioscience, Dunwoody Park, Atlanta, GA,
USA), Anti-COX-2 (e-Bioscience), HO-1 (Santa Cruz Biotechnology, Dallas, TX, USA), and anti-SOD
(Santa Cruz Biotechnology) antibodies were then added for a further 30 min. The secondary antibody
was added in Fix Solution, and cells’ fluorescence was evaluated using a fluorescence-activated
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cell sorter (FAC Sscan; Becton Dickinson) and elaborated with Cell Quest software as previously
described [44].
3.7. Data Analysis
Anti-inflammatory activity data are reported as mean ± standard error mean (S.E.M.) values of
independent experiments, performed at least three times, with three or more independent observations
in each. Statistical analysis was performed by analysis of variance test, and multiple comparisons were
made by Bonferroni’s test. A p-value less than 0.05 was considered significant.
3.8. Crystal Structure Determination
An air-stable single crystal of the compound was mounted on a glass fiber at a random orientation
on a Bruker Smart APEX II CCD diffractometer (Bruker AXS Inc., Madison, WI, USA). The data
collection was performed at 293 K byω-scan method in the interval 2 < θ < 22◦. The space group was
determined from the systematic absences, while the cell constants were refined at the end of the data
collection with the data reduction software SAINT [45]. The collected intensities were corrected for
Lorentz and polarization factors and empirically for absorption using the SADABS program [46].
The structures were solved by direct methods (SIR97) [47] and refined by full-matrix least-squares
on F2 (SHELXL-97 [48] and WINGX programs [49]) using anisotropic displacement parameters for all
atoms except for hydrogens (ORTEP view of 4 is given in Figure 6).
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Figure 6. ORTEPIII [50] plot of compound 4 showing the numbering schemes for all non-hydrogen
atoms. Ellipsoids drawn at 50% probability.
All the hydrogen atoms were located from a Fourier difference map and refined applying a
constraint on their isotropic dis la ements.
The main crystallographic data and structure refinement are collected in Table 1.
Table 1. Crystal data and structure refinement for 4.
Empirical Formula C2 H39 N O2
Formula weight 361.55
Temperature 293(2) K
Wavelength 0.71073 Å
Crystal system Orthorhombic
Space group P b c a
Unit cell dimensions a = 9.6110(10) Å
b = 9.70 0(10) Å
c = 48.575(6) Å
Volume 4529.9(9) Å3
Z 8
Density (calculated) 1.060 Mg/m3
Absorption coefficient 0. 66 mm−1
F(000) 1600
Theta range for data collection 0.838 to 22.490◦
Index ranges −10 ≤ h ≤ 10, −10 ≤ k ≤ 10, -51 ≤ l ≤ 52
Reflections collected 24670
Independent reflections 2959 [R(int) = 0.0472]
Completeness to theta 22◦ 99.6%
Refinement method Full-matrix least-squares on F2
Data/restraints/parameters 2959/0/352
Goodness-of-fit on F2 1.130
Final R indices [I > 2sigma(I)] R1 = 0.0528, wR2 = 0.1370
R indices (all data) R1 = 0.0848, wR2 = 0.1609
Largest diff. peak and hole 0.188 and −0.195 e·Å−3
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4. Conclusions
The aim of this study was to perform a screening of PEA derivatives/analogues compounds with
potential anti-inflammatory and antioxidant activity. The biological evaluation of compounds 1–6
clearly showed that two of them (4 and 5) possess good anti-inflammatory and antioxidant properties
without affecting the viability of J774A.1 macrophages. Moreover, for the most active compound,
4, a crystalline structure has been determined. As already shown in the case of receptor compounds
employed in the treatment of different CNS pathologies [51], further in vivo studies on these promising
compounds are needed to confirm the in vitro observations reported here.
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